A combination of GLP-1 and amylin analog has shown promise in reducing blood sugar and weight in diabetes trials. The treatment has been associated with modest weight loss and few gastrointestinal side effects, with some reports suggesting significant weight loss and improved blood sugar control. The specific outcomes and details of the treatment vary across different reports, with some mentioning specific medications and patient populations.